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The outcome of patients with end-stage renal disease on hemodialysis depends on a functioning vascular access. Although a variety
of access options are available, the arteriovenous fistula remains the best vascular access. Unfortunately the success rate of mature
fistula use remains poor. The creation of an arteriovenous fistula is followed by altered hemodynamic and biological changes that
may result in neointimal hyperplasia and eventual venous stenosis. This review provides an overview of these changes and the
needed research to provide a long lasting vascular access and hence improve outcomes for patients with end-stage renal disease.
1. Introduction
End-stage renal disease (ESRD) affects an increasing number
of patients each year with a staggering estimate of almost
640,000 patients receiving dialysis at the end of 2012 in the
United States [1]. The primary cause of ESRD is diabetes
followed by hypertension [1]. Patients with ESRD have a high
prevalence of concomitant cardiovascular disease, which is
the primary cause of morbidity and mortality in this patient
population [1]. The most common modality chosen for renal
replacement therapy is hemodialysis, for which a vascular
access is required. The vascular access choice influences and
contributes to the overall morbidity and mortality of the
patient [2, 3].
Hemodialysis vascular access type includes the preferred
arteriovenous fistula (AVF), the arteriovenous graft followed
by a central venous catheter [1, 2]. The best access to place
with least complications is the AVF. When an AVF is placed,
an artery is anastomosed to a vein and over a period of
2-3 months the vein becomes “arterialized,” a process that
is necessary prior to use of hemodialysis [4]. The first
access recommended is the lower arm radiocephalic fistula
(RCF) although these commonly fail especially in the elderly
and those with diabetes [5, 6]. The second preferred site
for an AVF is the brachiocephalic (BCF) which are being
placed at an increased number.The third fistula configuration
recommended is a brachiobasilic (BBF). The problem is that
many of these fistulas fail for unknown reasons. One-year
patency rates range from 60 to 65% [7, 8], with 60% of fistulas
not suitable for dialysis between 4 and 5months after surgery
[9]. Medical management with antiplatelet agents such as
ASA and Clopidogrel have failed to make a difference [10, 11].
This is likely due to the fact that these agents do not address
the primary cause of access failure, neointimal hyperplasia
(NH) leading to venous stenosis.
Once venous stenosis occurs with clinical symptoms such
as painful swelling of an extremity, skin ulceration, venous
hypertension, or subsequent poor function of the access,
treatment options include angioplasty, stent, or surgical
revision [12]. The treatment is dependent on the specific
site, characteristics, and hemodynamics of the lesion [12].
For example, the most common location for stenosis in a
RCF is near the anastomosis, while cephalic arch stenosis is
frequently encountered inBCF [12, 13]. Cephalic arch stenosis
is often treated with repeat angioplasty and stenting until
fistula failure occurs [13].
Venous stenosis as a result of NH is poorly under-
stood [14, 15]. There are multiple factors which influence
the outcome of an AVF including demographics, adjuvant
therapies, underlying histology, cytokines, oxidative stress,
and hemodynamics [16, 17]. There are few trials which look
at the biology of why a fistula fails or address treatment
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Figure 1: Schematic of a vessel. The white layer shows smooth
endothelial cells; the purple layer smooth muscle cells; 𝜌 shows
direction of pressure; 𝜏 shows direction of wall shear stress. Figure
reprinted by permission from Macmillian Publishers Ltd.: Nature
Reviews Molecular Cell Biology, 10, 2009.
options in prospective trials. This review highlights known
hemodynamic and biologic determinates of fistula failure and
suggest research areas which need to be explored.
2. Hemodynamics of
an Arteriovenous Fistula (AVF)
Creation of an AVF requires a surgical anastomosis of a
high pressure artery to a low pressure vein which causes an
increase in wall shear stress (WSS) and tension. The pressure
increase in the venous outflow tract will lead to medial
thickening, the definition of venous arterialization. Pressure
is defined as the perpendicular force (𝜌) exerted in a vessel,
whereas the WSS is the parallel force (𝜏) (Figure 1) [18].
Normally the luminal diameter will increase in an attempt
to reduce the WSS back to pre-AVF levels. The next result
is a dilated vein with a thickened media, the perfect vessel
for a fistula suitable for use for hemodialysis. Corpataux
et al. [19] summarized this phenomenon in a study where
hemodynamic changes were demonstrated in six patients
with a lower arm AVF using an ultrasound Doppler device.
Within the first week after fistula creation, the blood flow
and WSS increased substantially in the vein. The increased
flow resulted in a venous luminal diameter increase, a process
necessary for cannulation. The WSS gradually returned back
to normal by 12 weeks. In this study, findings were also
apparent at the arterial side, though to a lesser extent [19].
Problems arise in vasculature physics when a bend or
curve happens which is frequently the case especially when
an AVF is being constructed. Normal flow through a straight
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Figure 2: Schematic of a vessel with disturbed shear flow on the left
and laminar flow on the right. Figure reprinted by permission from
Macmillian Publishers Ltd.: Nature ReviewsMolecular Cell Biology,
10, 2009.
vessel is smooth and laminar as shown by the vessel on the
right side of Figure 2 [18].The endothelial cells in this instance
are at steady state, with low cell turnover, low permeability,
and low level of anti-inflammatory genes and oxidative stress.
The area of abnormal WSS (red) is minimal. However, when
a bend or curve arises laminar flow becomes turbulent as
shown in the left side of Figure 2 [18]. With turbulent flow
the endothelial cell turnover is high with poor alignment,
inflammatory genes activation, and increase in oxidative
stress. The area of abnormal WSS is much larger. Abnormal
turbulent flow causes low WSS, denuding endothelial cells,
excitation of pathways which eventually lead to NH [16]. Jia
et al. have recently shown in study of AVF creation in canines
that NH has a strong inverse correlation with WSS levels and
also is related to flow patterns [20].
3. Underlying Histology and Progression to
Neointimal Hyperplasia
The basic histology of an artery and a vein is very different
(Figure 3) [21]. A normal artery has a smooth endothelial
cell lining with the tunica intima defined as the boundary
of the endothelial cell to the elastic lamina. The tunica
media in an artery is normally much thicker than a vein
with an increased amount of elastin [21]. When a fistula is
created for hemodialysis, the patient often had chronic renal
failure for several years, which causes underlying changes
in the vein and artery including increased arterial and
venous calcification [22] and NH [23]. When a fistula is
then created, the changes in WSS and pressure sensed by
the endothelial cells signal vasodilating agents, such as nitric
oxide (NO), growth factors that control vascular smooth
muscle cell (VSMC) migration and proliferation, and cellular
adhesion molecules [17]. Upregulation of proteases such as
matrix metalloproteinase and cathepsins result in matrix
degradation and restructuring of the luminal expansion [17].
Little is known about the necessary outward remodeling of
























Figure 3: Schematic of an arterial wall on the left and venous wall on the right. Note increased tunica media in an arterial wall.
VSMC, although this is highly important [17]. In summary,
the underlying histology of the vessels used to create an AVF,
specifically calcification, elastin, and collagen deposition,
predicts the ability of a vein to dilate after fistula creation.
The morphometric and histologic characteristics of the
veins used for fistula creation have been studied. Lazich et
al. have shown that the vein used to create BCF is larger in
diabetics when compared to nondiabetics [24]. In particular
the internal lumen and intimal and medial area were all
found to be more dilated in diabetics [24]. This altered
remodelingmay be beneficial as previous reports have shown
that cephalic arch venous stenosis is attenuated in diabetics
with BCF [25–27]. Vascular wall remodeling differs between
diabetics and nondiabetics with increased NH in the former
[23, 24]. As NH progresses, this can dramatically decrease
the lumen size and lead to negative vascular remodeling and
vasoconstriction. All components of the vein including the
adventitia are now recognized as contributing to the process
of NH after fistula construction [8]. Most past research
focuses on NH although outward remodeling is an equally
important process that could preserve the vein lumen and
predict the outcome of the AVF over time [8]. This critical
balance between NH and outward remodeling in a vein when
a fistula is created requires further exploration.
4. Nitric Oxide (NO), Asymmetric
Dimethylarginine (ADMA), and
Vasodilator Effects
Fistula creation causes a passive vascular distension and a
dramatic release of NO from the endothelial cells [28]. The


















Figure 4: Schematic of vascular endothelium. Shear stress induces
calcium dependent activation of nitric oxide synthetase resulting
in smooth muscle relaxation. Figure reprinted by permission from
MolecularDiversity Presevation International: International Journal
Molecular Science, 13, 2012.
increased global shear stress which increases nitric oxide
synthetase converting L-arginine to NO (Figure 4) [28].
The NO activates soluble guanylyl cyclase (sGC) to cause
GTP to be converted to cyclic guanosine monophosphate
cyclic GMP causing smooth muscle cell relaxation. There is
a delicate balance between endothelial cell activation which
is needed for vein dilation and endothelial cell dysfunction
[29]. Endothelial cell dysfunction could result from increased
oxidative stress and lead to vasoconstriction and smooth
muscle cell proliferation which could result in NH and
contribute over time to access failure.
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A contributing factor to endothelial cell dysfunction
is a dramatic elevation of asymmetric dimethylarginine
(ADMA) known to be increased in patients with renal failure
[30]. ADMA, a metabolic by-product of protein metabolism
inhibits the conversion of L-arginine to NO, reducing vascu-
lar compliance, increasing vascular resistance, and limiting
blood flow [30]. Hammes et al. showed a 10-fold increase in
ADMA in patients with ESRD when compared to patients
without renal failure [31]. The procedure of hemodialysis
itself is also associated with an even greater rise in ADMA
[31]. Efforts to understand the complex pathway that leads to
devastating ESRD and corresponding vascular disease have
identified an accelerated calcific process, observed even in
small vessels. Elevated ADMA is a step in the pathway of
vascular disease in renal failure as it has been found to
contribute to CKD progression with an associated increase in
transforming growth factor TGF-𝛽1 and subsequent vascular
collagen deposition. [32]. The biologic effects of ADMA on
AVF contribute to venous stenosis [33] and are the subject of
future research investigation.
The vascular endothelium in an artery and vein respond
differently to blood flow, especially if there is associated
atherosclerosis [34]. The release of eNOS and resultant NO
is necessary for adequate vein dilation, a part of arterializa-
tion. Endothelial cells in arteries and veins are structurally
and functionally different including the ability to adjust to
changes in shear stress and release of eNOS [35]. There are
many inhibitors of NO, of most interest are Rho-kinases
(ROCKs). ROCKs are small guanosine triphosphate binding
proteins which mediate smooth muscle contraction, cell
migration, and proliferation by inhibition of eNOS [36].
Inhibition of ROCKs has been shown to decrease NH [37].
Molecular events which cause NO release are under the
control of ROCKs and warrant exploration in an AVFmodel.
5. Cytokines/Inflammation
Inflammation is a primary stimulus for NH.There is marked
upregulation in proinflammatory genes and progressive
neointimal formation in the venous vasculature in an AVF
which contributes to the aggressive venous stenosis observed.
Nath et al. [38] has shown an upregulation of genes including
TGF-𝛽1 which, in the venous vasculature in theAVFmodel in
the rat, are accompanied by intimal hyperplasia.NHoccurred
in variable degrees by 5 weeks after establishing a fistula,
and by 16 weeks, such NH was progressive and pronounced
with abundant extracellular matrix. In human subjects, levels
of inflammatory biomarkers have been harvested in surgi-
cally thrombosed fistulae. Pronounced intimal thickening in
stenosed fistulas was associated with expression of TGF-𝛽1
and insulin-like growth factor when compared to controls
[39].
Research in coronary artery bypass grafts has given clues
as to the mechanism of venous stenosis in arterialized veins
used for hemodialysis. Graft failure is common following
coronary artery bypass grafting [40, 41] puzzling vascular
biologists and surgeons as to mechanisms. Yuan et al. [42]
have shown that severe vascular wall degeneration and
collagen deposition together with overexpressed TGF-𝛽 sig-
naling cytokines were responsible for failure (early and late)
of the saphenous vein and radial artery grafts. As TGF-𝛽 is
responsible for NH in a number of vascular disease models
that have similarities to the arterialized vein in anAVF, targets
to impede this early gene signaling may be future directions
to help retard the aggressive NH which occurs in AVF.
6. Oxidative Stress of Dialysis
Patients with renal failure have several risk factors which pre-
dispose them to oxidative stress, including age, and underly-
ing disease including diabetes and hypertension. Hemodialy-
sis is a treatment which contributes to this oxidative stress by
evoking a dramatic change in the blood flow through a fistula.
The continuous volume and pressure changes as a result of
intradialytic volume gains can cause significant physiologic
stress on the endothelium of a vein. Moreover the hemodial-
ysis treatment itself has been shown to shear endothelial cells
and reduce nitric oxide formation [43]. When an access is
considered “mature” and cannulation begins, this could also
worsen the oxidative stress contributing to NH [44, 45].
Oxidative stress has been linked to atherosclerosis by
contributing to endothelial dysfunction and intima-media
thickness. Weiss et al. [46] used markers of oxidative stress
to study 11 AVF and 15 AVGs at the time of surgical resection
or revision. Markers of cell growth and proliferation were
endothelin-1 (ET-1), a potent mutagenic peptide implicated
in the formation of intimal hyperplasia: TGF-𝛽, a stimulus
to vascular cell growth and matrix production and platelet-
derived growth factor (PDGF), a mediator of intimal hyper-
plasia. All specimens studied showed significant NH. The
neointima close to the vascular lumen of the AVF and the
pseudointima close to the lumen of the ePTFE graft were
positive for oxidative stress markers. At sites of injury, as evi-
dent by histological inflammation and healing, expression of
oxidative markers was more intense. These findings support
intimal injury and resultant oxidative stress as a direct result
of fistula construction and cannulation contributing to NH.
7. Future Directions
Intensive research to determine the early events that trigger
NH in an arterialized vein is needed as the process of NH
starts when the fistula is created [17]. The optimal mismatch
of shear stress and pressure in both the vein and artery
are necessary to allow for some medial thickness without
aggressive NH setting in. Anastomotic design and strategies
and devices to define optimalWSS are in the process of being
developed [47]. Computational models have been developed
and are able to predict the clinical relevance of WSS in
predicting AVF maturation and venous stenosis [48–50].
Randomized clinical trials are needed to determine the utility
of CFD to improve AVF outcomes. NO production and
VSMC reorganization in outward remodeling in AVF likely
play a role in the ability of a vein tomature to support dialysis
and are targets of future research. Early vascular biological
events need to be unraveled.
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The current approach to placement of a vascular access
should be revisited. The goal of preoperative evaluation is
to provide a well-functioning access for a patient that will
last a life span of a patient with ESRD. Current work-up
includes physical exam, preoperative color duplex Doppler
ultrasound, and/or venogram to determine suitable arte-
rial/vein diameters and adequate blood flow. Assessment
of Doppler ultrasonographic assessment of flow-mediated
dilatation has been used to assess preoperative vascular
health but has not been found to predict fistula success [51].
The diameter of the vein has been shown to correlate with
successful outcome in some but not all studies [52]. The
intraluminal area and virtual histology available by such tools
as intravascular ultrasound enable a more indebt assessment
of endothelium [53]. This diagnostic procedure may provide
intraluminal images, allowing for more precise assessment
of veins, suitable and adequate for vein maturation, than
external luminal diameters provided by traditional methods.
A multifactorial approach evaluating arterial and venous
function is necessary to predict AVF success.
The definition of a mature AFV is vague. Current guide-
lines define a mature access as one that has a blood flow
of at least 600mL/min and is 6mm in diameter and less
than 6mm below the skin surface. In clinical practice, these
parameters cannot be reliably measured in an outpatient set-
ting. Recent investigation has defined the type of blood flow
in a fistula as an important determinate in maturation [54].
Cannulation techniques and skills must improve. Continued
education in the anatomy of the AVF and physical assessment
is crucial. New techniques for cannulation of difficult or
deep veins are being developed [55]. The rapid blood flow
with hemodialysis causes excessive turbulence and may not
be optimal to the endothelium of the arterialized vein,
predisposing to NH. We need to decrease inflammation as
much as possible with each dialysis treatment. Surveillance to
detect access dysfunction including high flow states needs to
be refined [56]. In summary, we must continue to investigate
the hemodynamics and vascular biology of the AVF and
develop better clinical parameters that confirm adequate AVF
function if the outcomes are going to improve.
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